Navigation Links
Mirixa Corporation and the APhA Foundation Form Partnership

APhA Foundation and NCPA Join Forces to Deliver Patient Care via Single

Platform, MirixaPro(SM)

RESTON, Va. and WASHINGTON, Oct. 9 /PRNewswire/ -- Mirixa Corporation and the American Pharmacists Association (APhA) Foundation, the creator of the Diabetes Ten City Challenge and a partner in the Asheville Project(R), jointly announced today that they will form a new partnership that will deliver all of APhA Foundation's HealthMapRx commercial programs via Mirixa. MirixaPro(SM) will be the platform of choice for all existing and future APhA Foundation commercial programs delivered through pharmacy.

This partnership joins the quality and reach of Mirixa-enabled patient care programs and services with the APhA Foundation's highly respected and nationally renowned employer-based disease management and wellness research efforts. Additionally, this enhanced alliance between the National Community Pharmacist Association (NCPA), which sponsors Mirixa, and the APhA Foundation represents a significant opportunity for the pharmacy community by providing enhanced opportunities to deliver patient care services.

"We are delighted to have earned the trust of the APhA Foundation and to be selected as their business partner and pharmacy platform of choice," expressed Rick Solano, Mirixa's Chief Executive Officer. "This partnership represents a significant step forward in enhancing pharmacy-based patient care and education services at the national level, and will help pharmacists improve consumer health and the quality of many lives," added Mr. Solano.

"This important collaboration between national pharmacist organizations has the tremendous potential to incentivize wellness, improve patient outcomes and manage costs, thereby addressing critical issues facing the U.S. healthcare system. The new partnership creates synergies that will provide enhanced service delivery and program offerings to current and future clients and responds to requests by our employer clients and pharmacists for integrated systems for patient care," said William Ellis, R.Ph., Executive Director and Chief Executive Officer of the APhA Foundation.

Mirixa will manage the new partnership and will begin integration and transition steps as soon as the partnership is finalized. All existing commercialized APhA Foundation programs will continue uninterrupted during the transition period. The APhA Foundation will continue to focus on its core mission to improve the quality of consumer health outcomes through demonstration projects, incentive grants, institutes and scholarship programs.

About the APhA Foundation

The American Pharmacists Association (APhA) Foundation, headquartered in Washington, D.C., is a non-profit organization affiliated with the American Pharmacists Association, the national professional society of pharmacists in the United States. The APhA Foundation has expertise in designing programs that seek to create a new medication use system in the United States where patients, pharmacists, physicians and other health care providers collaborate to dramatically improve the cost and quality of consumer health outcomes through the safe and effective use of medications. For additional information:

About Mirixa

Mirixa Corporation, sponsored by the National Community Pharmacists Association (NCPA), is the leader in targeted patient care services delivered via the nation's largest pharmacy-based patient care network. Dedicated to improving patients' health, Mirixa enables the healthcare community to deliver patient care services through retail pharmacy. Mirixa's web-based clinical application, MirixaPro(SM), is used by pharmacists to deliver standardized patient care services. For more information, please visit

Contacts: Christine Ryba Lisa Miller

703.865.2041 703.838.2682

SOURCE Mirixa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, will present at ... week in New York City . The ... December 1, 2015 at 9:30 a.m. EST. ... the website at least 15 minutes prior to the presentation ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... 23, 2015 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its preliminary unaudited financial results for the second quarter ... 30, 2015. --> --> ... Revenues for the second quarter of fiscal 2016 increased ...
(Date:11/23/2015)... The royalty-free a greement a ... for 112 low- and m iddle-i ... --> The Medicines Patent Pool (MPP) today announced ... agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral ... HCV virus.  The royalty-free licence will enable generic manufacture of ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):